Clariant delivered strong growth in Q4 2021 and record profitability in FY 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
- Independent investigation concluded – Full Year 2020 (restated) and 2021 audited
- Fourth Quarter 2021:Sales from continuing operationsgrew by 23% in local currency to CHF 1.242 billion driven by strong pricing and volume expansion
- Fourth Quarter 2021:EBITDA margin increased to 16.3% from 16.1 % supported by operating leverage and continued higher pricing,which diminishedongoing raw material, energy, and logistics cost inflation
- Full Year 2021:Sales from continuing operations increased by 15 % in local currency to CHF 4.372 billion
- Full Year 2021:EBITDA margin increased to 16.2 % from 15.5 % in a supportive demand environment – highest EBITDA margin since 1999
- Full Year 2021: Net result for total Group at CHF 373 million
- Full Year 2021: Strong operating cash flow of CHF 363 million despite higher growth-related net working capital and restructuring cash-out
- Distribution of CHF 0.40 per shareproposed to AGM on 24 June2022
- Outlook 2022: Stronglocal currency growth for the Group with the aim to improveyear-on-year Group EBITDA margin level in a challenging geopolitical environment
“Clariant concluded the independent investigation and today presented its audited full year 2021 financials. We are pleased to announce markedly higher organic sales growth and a record profitability level in 2021 which is also well above 2019 pre-COVID-19 pandemic levels. We were able to successfully manage the challenges from unprecedented developments in raw materials, as well as energy and logistics cost. These results positively reflect the attractiveness of the Group’s higher-value specialty portfolio and provide tangible proof of the continued effective execution of cost discipline and our performance improvement programs,” said Conrad Keijzer, CEO of Clariant. “In 2022, we will continue to execute Clariant’s strategy to deliver profitable growth, guided by our new purpose: Greater Chemistry – between people and planet. I would like to take this opportunity to thank all our people for their dedication and hard work, which is reflected by these strong 2021 results, as well as our customers and suppliers for placing their trust in Clariant.”
Key Financial Data1
|Continuing operations||Fourth Quarter||Full Year|
|in CHF million||2021||2020||% CHF||% LC||2021||2020||% CHF||% LC|
|Sales||1 242||1 022||22||23||4 372||3 860||13||15|
|- margin||16.3 %||16.1 %||16.2 %||15.5 %|
|EBITDA before exceptional items||230||179||28||760||623||22|
|- margin||18.5 %||17.5 %||17.4 %||16.1 %|
|Return on invested capital (ROIC)||9.9 %||7.4 %|
|Net result from continuing operations||292||130|
|Net result (2)||373||825|
|Operating cash flow (2)||363||369|
|Number of employees as of 31 December (2)||13 374||13 235|
|Discontinued operations (3)|
|Net result from discontinued operations||81||695|
(1) FY 2020 restated, Q4 2020 corrected
(2) Total Group including discontinued operations
(3) Masterbatches divested on 1 July 2020
Fourth Quarter 2021 –Strong growth with higher profitability
MUTTENZ, MAY19, 2022
Clariant, a focused, sustainable, and innovative specialty chemical company, today announced its Fourth Quarter 2021 and audited Full Year 2021 results. Following the independent investigation, the 2020 Full Year and quarterly results have been restated and the quarters of 2021 have been corrected accordingly. The restatements in the 2020 Annual Financial Statement resulted in an EBITDA increase of CHF 19 million and CHF 14 million in net result from continuing operations. The fourth quarter continuing operations sales were CHF 1.242 billion, compared to CHF 1.022 billion in the fourth quarter of 2020. This corresponds to an increase of 23 % in local currency and 22 % in Swiss francs. Both pricing, which addressed continued cost inflation, and volume growth had a positive impact on the Group of 14 % and 9 %, respectively. Care Chemicals and Natural Resources grew sales strongly, which more than compensated for the expected development in Catalysis.
All geographic regions contributed to the sales expansion in the fourth quarter of 2021, reflecting both a demand recovery as well as shortages in supply chains. In Europe, the lofty 25 % local currency growth was underpinned by strong expansion in Care Chemicals. The 12 % growth in Asia-Pacific was driven by 17 % expansion in China while sales in North America increased by 17 %. The 30 % sales growth in Latin America and 76 % expansion in the Middle East & Africa, the smallest region, were underpinned by all Business Areas.
In the fourth quarter of 2021, Care Chemicals increased sales by 39 % in local currency. This was supported by organic double-digit expansion in Industrial Applications and Consumer Care, Crop Solutions, and Aviation in particular, in addition to the consolidation of the acquired majority share in Clariant IGL Specialty Chemicals (CISC) and the result of acquiring the remaining shares in Beraca, whose sales contributions exceeded expectations. Catalysis sales remained unchanged in local currency, primarily due to the expansion in Syngas, Specialty Catalysts, and the emission-control businesses, which largely counterbalanced the weakness in parts of Petrochemicals. Natural Resources sales increased by a notable 25 % in local currency with growth attributable to all three Business Units, Additives in particular.
The continuing operations EBITDA increased to CHF 203 million and a corresponding margin of 16.3 %, slightly exceeding the 16.1 % reported in the fourth quarter of the previous year. The development was underpinned by higher sales, operating leverage, pricing measures largely offsetting raw material price increases, and the ongoing execution of Clariant’s performance programs, which contributed additional cost savings of CHF 13 million, including the efficiency programs, in the fourth quarter of 2021. The absolute profitability almost matched the high CHF 208 million pre-pandemic level generated in the fourth quarter of 2019 despite negative currency effects.
Full Year 2021 – Specialty chemicals portfolio delivered further sales and profitability improvement
In the full year 2021, continuing operations sales were CHF 4.372 billion, compared to CHF 3.860 billion in full year 2020. This corresponds to an increase of 15 % in local currency and 13 % in Swiss francs. Both pricing and volume growth had a positive impact on the Group of 8 % and 7 %, respectively.
In the full year 2021, sales rose in almost all geographic regions. The developments in Europe, the Middle East & Africa, Asia-Pacific, including China, and Latin America were particularly robust with sales expansion in the range of 16 % to 20 %. The sales gap in North America continued to dwindle and the region ended the year unchanged versus the previous year levels due to the ongoing recovery in Oil and Mining Services.
Care Chemicals sales rose by 22 % in local currency in the full year 2021 with a double-digit organic sales increase in both Industrial Applications and Consumer Care. In Catalysis, the top-line was up by 5 % in local currency, supported by Syngas, Specialty Catalysts, and emission-control catalyst demand. Oil and Mining Services, Functional Minerals, and particularly Additives all contributed to the 14 % local currency sales growth reported in Natural Resources.
The continuing operations EBITDA increased to CHF 708 million as the Group improved profitability on the back of notable sales expansion, operating leverage together with the continued successful pricing measures largely offsetting raw material price increases of approximately 21 %, and the execution of the performance improvement programs, which resulted in additional cost savings of CHF 41 million in the full year 2021. Clariant recognized a CHF 33 million net VAT-related credit over the full year 2021, which was offset by exceptional cost, largely related to the performance improvement programs. The EBITDA margin increased to 16.2 % from 15.5 % in the previous year due to the profitability improvement in Care Chemicals and Natural Resources and the continued cost discipline across the Group.
In 2021, the total Group net result was CHF 373 million versus CHF 825 million in the previous year, CHF 102 million excluding the gain on the Masterbatches disposals. The 2021 net result was positively affected by the strong business performance of the continuing operations and the corresponding margin improvement. In 2020, the gain on the disposal of the Masterbatches business of CHF 723 million and the partial reversal of CHF 50 million of the EU fine provision had an extraordinary positive impact on the result.
Operating cash flow for the total Group was CHF 363 million, just slightly below the previous year level of CHF 369 million, despite a growth-driven cash outflow in net working capital of CHF 221 million, which resulted from the marked sales increase as well as supply chain uncertainties. The restructuring cash payments of CHF 38 million also negatively impacted the cash flow development.
Net debt for the total Group increased to CHF 1.535 billion versus CHF 1.040 billion recorded at the end of 2020. This development is attributable to a growth-driven increase in working capital, higher investments into property, plant, and equipment as well as acquisitions.
The Board of Directors recommends a regular distribution of CHF 0.40 per share to the Annual General Meeting (AGM) on 24 June 2022 based on the strong performance in 2021. This distribution represents an attractive pay-out ratio of 49 % of continuing operations earnings per share (EPS: CHF 0.81) and is proposed to be made through capital reduction by way of par value reduction.
The Board of Directors proposes the reelection of Günter von Au as Chairman. The following Board of Directors members will not stand for reelection at the 2022 AGM: Abdullah Mohammed Alissa, Nader Ibrahim Alwehibi, and Calum MacLean. The Board of Directors thanks them for their contribution to Clariant and therefore proposes the election of the following individuals: Ahmed Mohamed Alumar, Saudi Arabian Citizen; Roberto César Gualdoni, German and Italian Citizen; Naveena Shastri, US Citizen.
In the fourth quarter of 2021, Pigments sales increased by 21 % in local currency and by 20 % in Swiss francs. In the full year 2021, on a like-for-like basis, excluding Masterbatches sales from the first half of 2020, Pigments sales in discontinued operations rose by 15 % in local currency and by 14 % in Swiss francs due to the improved economic environment.
In the fourth quarter of 2021, the EBITDA margin in discontinued operations increased to 8.8 % due to the higher sales levels, the corresponding operating leverage improvement in Pigments, the execution of the efficiency program, as well as effects from other discontinued operations.
In the full year 2021, the EBITDA margin in discontinued operations was 12.5 %.
Outlook – Full Year 2022
Clariant aims to grow above the market to achieve higher profitability through sustainability and innovation. The Group has concluded its significant portfolio transformation program by divesting Healthcare Packaging in 2019, Masterbatches in 2020, and Pigments in January of 2022. Clariant is now a truly specialty chemical company and confirms its 2025 ambition to deliver profitable growth (4 – 6 % CAGR), a Group EBITDA margin between 19 – 21 % and a free cash flow conversion of around 40 %.
In the first quarter of 2022, Clariant expects to generate continued strong sales growth in local currency versus the prior year, underpinned by expansion in Care Chemicals and Natural Resources despite a normalizing growth environment. Clariant is aiming to sustain its corrected year-on-year margin levels in the first quarter of 2022 via volume growth, continuing pricing actions, and cost discipline to diminish continued inflation in raw materials, logistics, labor, and energy cost.
For the full year 2022, Clariant expects strong growth in local currency for the Group driven by a particularly strong first half of 2022. The current high level of uncertainty as a result of the geopolitical conflicts, suspension of business in Russia and the resurgence of COVID-19 in China are expected to impact global economic growth and consumer demand in the second half of the year. Clariant expects the high inflationary environment with regard to raw material, energy and logistic cost as well as supply chain challenges to persist in the second half of 2022. Clariant aims to improve its year-on-year Group EBITDA margin levels via solid volume growth, continued cost discipline, and pricing in an overall increasingly challenging economic environment.
Clariant intends to publish its Integrated Report 2021 on 2 June 2022 and the First Quarter 2022 results on 15 June 2022. The virtual Annual General Meeting 2022 is scheduled for 24 June 2022.
Please note that all information provided in this document references the FY 2020 restated and Q4 2020 corrected results. For details regarding the restatements please refer to the Fourth Quarter / Full Year 2021 Analyst Presentation and the Financial Review – Full Year 2021, available on the Clariant website: Latest Results (clariant.com)
|CORPORATE MEDIA RELATIONS|
Phone +41 61 469 63 63
Phone +41 61 469 63 63
Phone +41 61 469 63 63
Phone +41 61 469 63 73
Phone +41 61 469 63 73
Phone +41 61 469 63 73
|Follow us on Twitter, Facebook, LinkedIn, Instagram.|
This media release contains certain statements that are neither reported financial results nor other historical information. This document also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements. Many of these risks and uncertainties relate to factors that are beyond Clariant’s ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators and other risk factors such as: the timing and strength of new product offerings; pricing strategies of competitors; the Company’s ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials.
Clariant is a focused, sustainable and innovative specialty chemical company based in Muttenz, near Basel/Switzerland. On 31 December 2021, the company employed a total workforce of 13 374. In the financial year 2021, Clariant recorded sales of CHF 4.372 billion for its continuing businesses. The company reports in three Business Areas: Care Chemicals, Catalysis, and Natural Resources. Clariant’s corporate strategy is led by the overarching purpose of ”Greater chemistry – between people and planet,” and reflects the importance of connecting customer focus, innovation, sustainability, and people.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 202224.6.2022 22:05:00 CEST | Press release
REPORT –ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022 Cambridge, MA (U.S.) and Lyon (France), June24, 2022 – ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announcedthat its Annual General Meeting was held on Friday, June 24, 2022. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including: Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2021;Allocation of the financial year's results;Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2021, to Gil BEYEN, Chief Executive Officer and Jean-Paul KRESS, Chairman of the Board;Approval of the compens
Cleantech Building Materials: Results of Annual General Meeting24.6.2022 14:54:27 CEST | Press release
24 June 2022 CLEANTECH BUILDING MATERIALS PLC, NASDAQ FIRST NORTH GROWTH MARKET, COPENHAGEN TICKER: CBM ISIN: GBOOBD1LVD21 CLEANTECH BUILDING MATERIALS PLC Results of Annual General Meeting The Annual General Meeting (“AGM”) of Cleantech Building Materials plc (“CBM” or the “Company”) was held in London earlier today, 24 June 2022. Details of the resolutions to be considered at the AGM were published in the Notice of AGM which was posted to Shareholders on 1 June 2022 and is available on the Company’s website: www.cbm-plc.com. All resolutions as set out in the Notice of AGM were duly passed without discussion. In particular, the following resolutions were passed at the AGM. The AGM resolved to authorise the directors of the Company to allot shares and grant rights to subscribe for, or convert any security, into shares. The directors of the Company sought authority for the purposes of section 551 of the Companies Act to exercise all the powers of the Company to allot shares and grant ri
Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia24.6.2022 13:13:19 CEST | Press release
With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least two prior tyrosine kinase inhibitor treatments1 Positive opinion based on data from pivotal Phase III ASCEMBL trial, showing a near doubling in major molecular response rate for patients treated with Scemblix® (asciminib) vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) and more than three times lower discontinuation rate due to adverse reactions (5.8% vs 21.1%) at 24 weeks1 CHMP recommendation comes after the approval of Scemblix by the US FDA and other countries’ regulatory authorities, potentially broadening access for more patients to Novartis transformative therapies in CML Basel, June 24, 2022 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing au
Clariant’s shareholders approve all agenda items24.6.2022 11:30:00 CEST | Press release
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Integrated Report and Group Consolidated Financial Statements for fiscal year 2021 approvedGünter von Au reelected as Chairman of the Board of DirectorsThree new candidates join the Board of Directors: Ahmed Mohamed Alumar, Roberto César Gualdoni, Naveena ShastriConfirmed distribution of CHF 0.40 per shareKPMG confirmed as statutory auditor from 2022 MUTTENZ, JUNE 24, 2022 Clariant, a focused, sustainable, and innovative specialty chemical company, today held its 27th Annual General Meeting (AGM) where the shareholders approved all agenda items and resolutions as proposed by the Board of Directors. The AGM was held virtually, where shareholders were able to exercise their rights exclusively via the independent proxy. Overall, 698'945'298 shares or around 70.19 % of the share capital of Clariant were represented. Günter von Au was reelected as Chairman of the Board of Directors. Additionally, three new members were voted to join by a large majo
Cool Company Ltd. – Mandatory Notification Of Trade24.6.2022 11:01:19 CEST | Press release
EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 23 June 2022 acquired 7,865 shares in the Company at a price of NOK 90.274882 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,591,218 shares in the Company, equivalent to 38.97% of the Company’s shares. Please see the attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Primary insider notification form